2. Anti-infection
  3. SARS-CoV
  4. Paquinimod

Paquinimod  (Synonyms: ABR-215757; ABR 25757)

Cat. No.: HY-100442 Purity: 99.90%
COA
SDS
Handling Instructions Technical Support

Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.

For research use only. We do not sell to patients.

CAS No. : 248282-01-1

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 33 publication(s) in Google Scholar

Other Forms of Paquinimod:

Paquinimod Related Antibodies

Top Publications Citing Use of Products

33 Publications Citing Use of MCE Paquinimod

In Vivo Efficacy Study
Histological Imaging/Staining
ELISA
In Vivo Imaging

    Paquinimod purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2025 Nov 26:S0016-5085(25)05987-6.  [Abstract]

    Colitis histology score of WT mice exposed to DSS and treated with Paquinimod (10 mg/kg/d, p.o., 7d) or vehicle.

    Paquinimod purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2025 Nov 26:S0016-5085(25)05987-6.  [Abstract]

    Representative H&E images of WT mice exposed to DSS and treated with Paquinimod (10 mg/kg/d, p.o., 7d) or vehicle.

    Paquinimod purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2025 Nov 26:S0016-5085(25)05987-6.  [Abstract]

    Quantification of human recombinant S100A9 homodimers in the presence of increasing concentrations of Paquinimod, as determined by ELISA.

    Paquinimod purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Nov;281(Pt 1):136178.  [Abstract]

    Paquinimod (HY-100442;ip; 15 mg/kg/d for seven days) and p38 MAPK-IN-1 (HY-12839; ip; 1 mg/kg/d for seven days ) both reduced the renal deposition of calcium in nephrocalcinosis mice.

    Paquinimod purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Nov;281(Pt 1):136178.  [Abstract]

    Paquinimod (HY-100442;ip; 15 mg/kg/d for seven days) and p38 MAPK-IN-1 (HY-12839; ip; 1 mg/kg/d for seven days ) both reduced the renal deposition of calcium in nephrocalcinosis mice.

    Paquinimod purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Nov;281(Pt 1):136178.  [Abstract]

    Paquinimod (HY-100442;ip; 15 mg/kg/d for seven days) and p38 MAPK-IN-1 (HY-12839; ip; 1 mg/kg/d for seven days ) both reduced the renal deposition of CaOx crystals in nephrocalcinosis mice.

    Paquinimod purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2023 Jun 14;31(6):1054-1070.e9.  [Abstract]

    Barplot showing reduced lung function in emphysema mice treated with homocysteine, which was reversed by S100A8/A9 inhibitor Paquinimod (3.75mg/kg, i.g. every other day over four weeks, n = 5/group).

    Paquinimod purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2023 Jun 14;31(6):1054-1070.e9.  [Abstract]

    Barplot for histopathological score showing increased lung tissue injury in emphysema mice treated with homocysteine, which was reversed by S100A8/A9 inhibitor Paquinimod (3.75mg/kg, i.g. every other day over four weeks, n = 5/group).

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice[1][2][3].

    IC50 & Target

    S100A9[1]
    In Vivo

    S100A9 is a calcium-binding protein of the S100 family. Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. Prophylactic treatment with S100A9 inhibitor Paquinimod reduces pathology in experimental collagenase-induced osteoarthritis[1]. Paquinimod is a potent inhibitor of insulitis and diabetes development in the NOD mouse. To assess the preventive efficacy of Paquinimod on diabetes development in female NOD mice, groups of mice are treated with daily doses of 0.04, 0.2, 1, and 5 mg/kg/day of Paquinimod from week 10 of age until week 20 of age. Glycosuria is analyzed on a weekly basis from 10 weeks of age until the endpoint of the experiment at 40 weeks of age. There is a clear dose-dependent reduction in diabetes development in the Paquinimod-treated mice[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    350.41

    Formula

    C21H22N2O3
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(C1=C(O)C2=C(C=CC=C2CC)N(C)C1=O)N(CC)C3=CC=CC=C3
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 62.5 mg/mL (178.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.8538 mL 14.2690 mL 28.5380 mL
    5 mM 0.5708 mL 2.8538 mL 5.7076 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.08 mg/mL (5.94 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 5 mg/mL (14.27 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.90%

    SDS (396 KB)

    COA (251 KB) LCMS (94 KB)

    Handling Instructions (2659 KB)
    References
    Animal Administration
    [2]

    Mice[2]
    Female NOD/MrkTac mice are exposed to increasing concentration of CO2 and upon loss of consciousness euthanized by cervical dislocation. To investigate the effect of the Q-compound Paquinimod on development of glycosuria and insulitis, mice are treated with Paquinimod dissolved in drinking water at different concentrations corresponding to daily doses of about 0.04, 0.2, 1, and 5 mg/kg body weight/day). The mice are treated with Paquinimod starting from either 10 or 15 weeks of age. The duration of treatment varies from 5 to 23 weeks in the different experiments performed[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.8538 mL 14.2690 mL 28.5380 mL 71.3450 mL
    5 mM 0.5708 mL 2.8538 mL 5.7076 mL 14.2690 mL
    10 mM 0.2854 mL 1.4269 mL 2.8538 mL 7.1345 mL
    15 mM 0.1903 mL 0.9513 mL 1.9025 mL 4.7563 mL
    20 mM 0.1427 mL 0.7134 mL 1.4269 mL 3.5672 mL
    25 mM 0.1142 mL 0.5708 mL 1.1415 mL 2.8538 mL
    30 mM 0.0951 mL 0.4756 mL 0.9513 mL 2.3782 mL
    40 mM 0.0713 mL 0.3567 mL 0.7134 mL 1.7836 mL
    50 mM 0.0571 mL 0.2854 mL 0.5708 mL 1.4269 mL
    60 mM 0.0476 mL 0.2378 mL 0.4756 mL 1.1891 mL
    80 mM 0.0357 mL 0.1784 mL 0.3567 mL 0.8918 mL
    100 mM 0.0285 mL 0.1427 mL 0.2854 mL 0.7134 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Paquinimod Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Paquinimod248282-01-1ABR-215757 ABR 25757ABR215757ABR 215757ABR25757ABR 25757ABR-25757SARS-CoVSARS coronavirusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Paquinimod
    Cat. No.:
    HY-100442
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.